Barth Syndrome Treatment Market
According to Intent Market Research, the Barth Syndrome Treatment Market is expected to grow from USD 0.4 billion in 2023 at a CAGR of 12.7% to touch USD 0.8 billion by 2030. The Barth Syndrome Treatment Market is dominated by key players such as, GlaxoSmithKline Plc, Pfizer Inc., AbbVie Inc., Alnylam Pharmaceuticals, and Amgen Inc.